Exercise, fall risk, caregiver burden focus of UAMS Parkinson’s meeting
Physical exercise, avoiding falls, and the importance of providing support to caregivers were the focus of the 10th UAMS…
Articles by Andrea Lobo
Psilocybin eases depression, anxiety in Parkinson’s: Pilot trial
Low-dose psilocybin, a naturally occurring psychedelic compound, may be a promising therapy for mood issues including depression and anxiety in…
IC 100 reduces inflammasome activation, alpha-synuclein clumps
Blocking the inflammatory protein ASC with IC 100, ZyVersa Therapeutics’ experimental therapy to reduce inflammation, prevented the activation of…
STING protein-linked inflammation may have role in Parkinson’s
The STING protein, which has been linked to cell damage and brain inflammation — two known contributing factors to…
New AI tool may predict different structures of amyloid fibrils: Study
A new artificial intelligence (AI) tool may help predict the structure of amyloid fibrils, that is, misfolded protein fibers that…
AAN 2025: Less off time, more good on time with long-term Onapgo
Treatment for up to three years with Onapgo (apomorphine hydrochloride) — approved in the U.S. earlier this year as…
Excess exercise may worsen Parkinson’s symptoms, report says
Although physical exercise has well-established benefits for people with Parkinson’s disease, too much of it may worsen fatigue and…
AAN 2025: Vyalev has good long-term safety profile in Parkinson’s
Vyalev (foscarbidopa and foslevodopa) demonstrated a favorable long-term safety and tolerability profile, along with sustained motor symptom control,…
Parkinson’s therapy slows alpha-synuclein spread in mice: Data
Nitrase Therapeutics’ NDC-0524, an antibody therapy for Parkinson’s disease, significantly reduced alpha-synuclein aggregation and spreading in mouse models of the…
Collaboration to expand access to alpha-synuclein protein test in US
A new collaborative effort between Mayo Clinical Laboratories and Amprion will expand access to the diagnostic company’s…